FindTrial
Sign In

laromustine

DRUG12 trials

Sponsors

Vion Pharmaceuticals, Pediatric Brain Tumor Consortium, Institut Paoli-Calmettes

Conditions

Brain and Central Nervous System TumorsLeukemiaLung CancerLymphomaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmsSmall Intestine CancerUnspecified Adult Solid Tumor, Protocol Specific

Phase 1

VNP40101M in Treating Patients With Advanced or Metastatic Cancer
CompletedNCT00049699
Vion PharmaceuticalsLymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Start: 2002-10-31End: 2008-01-31Updated: 2013-07-18
VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas
CompletedNCT00025129
Vion PharmaceuticalsLymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Start: 2001-03-31End: 2004-05-31Updated: 2013-07-18
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
CompletedNCT00049686
Vion PharmaceuticalsLeukemia, Myelodysplastic/Myeloproliferative Neoplasms, Myelodysplastic Syndromes
Start: 2002-04-30End: 2008-01-31Updated: 2013-07-18
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
CompletedNCT00070538
Vion PharmaceuticalsLeukemia, Myelodysplastic Syndromes
Start: 2003-06-30End: 2008-01-31Updated: 2013-07-18
Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias
CompletedNCT00098436
Vion PharmaceuticalsLeukemia
Start: 2004-09-30End: 2008-08-31Target: 25Updated: 2013-07-18
VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors
CompletedNCT00098761
Pediatric Brain Tumor ConsortiumBrain and Central Nervous System Tumors
Start: 2005-02-28End: 2008-02-29Updated: 2011-06-30
VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders
CompletedNCT00304005
Vion PharmaceuticalsLeukemia, Lymphoma
Start: 2005-07-31End: 2008-08-31Target: 35Updated: 2013-07-18
Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia
CompletedNCT00840684
Institut Paoli-CalmettesLeukemia
Start: 2009-01-31Target: 135Updated: 2011-05-13

Phase 2

VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia
CompletedNCT00083187
Vion PharmaceuticalsLeukemia, Myelodysplastic/Myeloproliferative Neoplasms, Myelodysplastic Syndromes
Start: 2005-11-30End: 2008-08-31Target: 230Updated: 2013-07-18
VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer
CompletedNCT00282022
Vion PharmaceuticalsLung Cancer
Start: 2005-09-30Target: 87Updated: 2013-11-06
VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia
NCT00354276
Vion PharmaceuticalsLeukemia
Start: 2006-05-31Target: 85Updated: 2014-01-10

Phase 3

Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia
CompletedNCT00112554
Vion PharmaceuticalsLeukemia
Start: 2005-03-31End: 2008-03-31Target: 420Updated: 2013-11-06

Related Papers

Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.
2009-08-2632 citations